Professor Sanfilippo was one of ten new faculty hires made in the School of Molecular and Cellular Biology in the last three years. Sanfilippo is an assistant professor of biochemistry.
The School of Molecular & Cellular Biology is proud to have accomplished ten new faculty hires over the last three years! These strategic hires have been made in areas of brain plasticity, virology and immunology, developmental biology, and microbiology. These outstanding new recruits,...
Recent clinical trials involving Fragile X Syndrome (FXS), a genetic disorder that causes mild to severe intellectual disability, indicate that potential drug treatments are not as effective as researchers initially hoped. This lack of therapeutic potential suggests there are some gaps in our...
New mutations to the coronavirus that causes COVID-19 are emerging, including one in the United Kingdom with higher infection rates that has sparked new travel bans. Erik Procko, a professor of biochemistry at the University of Illinois Urbana-Champaign, has been studying mutations in the spike...
It has been over 60 years since scientists first identified the molecule that we know today as immunoglobulin (Ig) A. IgA is the predominant class of antibody found in human mucus where it is known as secretory (S) IgA. SIgA functions to bind microbes in extracellular regions such as the gut and...
Current cancer treatments include drugs that target standard protein synthesis in cells, which can kill cancer cells, but also targets healthy cells. To address this issue, associate professor of biochemistry and Cancer Center at Illinois (CCIL) member, Hong Jin, is focusing on a non-canonical...
New research by biochemistry professor Kai Zhang and his team at the University of Illinois uses the groundbreaking field of optogenetics to show a potential new route for controlling specific neuron growth with incredible accuracy. Their recent paper “Optical control of ERK and AKT signaling...
University of Illinois researchers are leading the science behind a new global licensing agreement between the pharmaceutics company Bayer AG and the cancer drug development company Systems Oncology for a new breast cancer drug called ERSO.